Thierry Hercend

Biography

  Dr. Thierry Hercend, M.D., Ph.D., is a Venture Partner at Edmond de Rothschild Investment Partners, S.A.S. Dr. Hercend is a part of the life sciences team. Dr. Herchend also serves as an Independent Consultant for biotechnology companies. Dr. Hercend served as a Vice-President for Research Europe at Vertex Pharmaceuticals and a Vice-President and Head of Preclinical Oncology Research at Aventis. He held executive positions in several companies, including a Director of the Immunology Therapeutic Department at Roussel-Uclaf and as the Chief Scientific Officer at the LFB (Laboratoire Français du Fractionnement et des Biotechnologies). He was a Professor of Immunology at the University of Paris and Head of the Immuno-Hematology Laboratory at the Gustave Roussy Cancer Institute. Dr. Hercend serves as the Director of Poxel SA. He has been the Chairman of the Supervisory Board of Genticel S.A. since July 31, 2008. He serves as a Member of Supervisory Board of U3 Pharma AG. He served as Chairman of the Board at Poxel SA until April 18, 2016. He has published more than 120 papers in peer reviewed international journals in the field of Immunology, Transplantation and Oncology. He has six years of experience in private equity. Dr. Hercend holds the degrees of Doctor of Immunology and Doctor of Medicine from the University of Paris

Research Interest

   Immunology